Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pathway-Based Analysis of Essential Metabolic Enzymes as Drug Targets

Created on 27 Oct 2026

Authors

Bhat, D. S., Singh, B.

Abstract

Tuberculosis (TB) , caused by Mycobacterium tuberculosis , remains a major global health crisis, aggravated by rapid emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR) strains. Conventional drug discovery is time-consuming and expensive, making computational target identification and drug repurposing as crucial strategies to accelerate the development of novel antitubercular therapies. This study aimed to identify and prioritize the metabolic enzymes as potential drug targets through pathway based analysis and to screen the FDA-approved drug library for potential canidates for drug repurposing. Based on the pathway analysis, para-aminobenzoate synthase component I (PabB) was selected as a potential drug target owing to its role in folate biosynthesis. Subesquently, an FDA-approved drug library was screened based on ADMET properties and selected compounds were used for molecular docking agaist the protein. Molecular docking through DiffDock and validation using GNINA revealed that Ligand 5 and Ligand 27 exhibit favourable interaction profiles within the binding region of PabB, and emerged as potential candidates for further investigation in drug repurposing. The identification of PabB protein asan essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 27 Oct 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement